{"entity":{"id":"nct04844866","kind":"trial","name":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","aka":[],"tldr":"A phase 2 trial of Zamtocabtagene autoleucel, Rituximab, Gemcitabine in diffuse large b-cell lymphoma, run by Miltenyi Biomedicine GmbH, now recruiting.","summary":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients is a phase 2 interventional study registered as NCT04844866 by Miltenyi Biomedicine GmbH, with 213 participants planned, started 2021-08-18 and due to reach its primary completion in 2025-01-15. Interventions recorded: MB-CART2019.1, Standard of Care. Conditions listed: Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04844866","url":"https://clinicaltrials.gov/study/NCT04844866"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["zamtocabtagene-autoleucel","rituximab","gemcitabine","capox","polatuzumab-vedotin","bendamustine"],"companies":["miltenyi-biomedicine"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04844866","phase":"2","setting":"A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT","sponsor":"Miltenyi Biomedicine GmbH","enrolled":213,"outcomes":[]},"route":"/trials/nct04844866/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"zamtocabtagene-autoleucel","kind":"drug","name":"Zamtocabtagene autoleucel","route":"/drugs/zamtocabtagene-autoleucel/"}],"company":[{"id":"miltenyi-biomedicine","kind":"company","name":"Miltenyi Biomedicine","route":"/companies/miltenyi-biomedicine/"}]}}